Serotonergic involvement in the amelioration of behavioral abnormalities in dopamine transporter knockout mice by nicotine

Neuropharmacology

Volumn 64, Issue , 2013, Pages 348-356

  Uchiumi, Osamu ^a   Kasahara, Yoshiyuki ^a   Fukui, Asami ^a   Hall, F Scott ^b   Uhl, George R ^b   Sora, Ichiro ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

4 2 nACh receptor; 7 nACh receptor; 5 HT1A receptor; Locomotor activity; Prepulse inhibition; Schizophrenia

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; DIHYDRO BETA ERYTHROIDINE; DOPAMINE TRANSPORTER; MECAMYLAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NICOTINE TARTRATE; SEROTONIN 1A RECEPTOR;

ACOUSTIC REFLEX; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FEMALE; HABITUATION; HYPERACTIVITY; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOUSE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSORY GATING; SEROTONINERGIC SYSTEM; STARTLE REFLEX;

ANIMALS; BEHAVIOR, ANIMAL; COGNITION DISORDERS; CROSSES, GENETIC; DISEASE MODELS, ANIMAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DRUG INTERACTIONS; FEMALE; MALE; MICE; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NEURAL INHIBITION; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; NOOTROPIC AGENTS; PSYCHOMOTOR DISORDERS; RECEPTOR, SEROTONIN, 5-HT1A; SCHIZOPHRENIA; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS;

EID: 84866399418     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.07.016     Document Type: Article

References (70)

1. J.B. Acri, D.E. Morse, E.J. Popke, and N.E. Grunberg Nicotine increases sensory gating measured as inhibition of the acoustic startle reflex in rats Psychopharmacology (Berl.) 114 1994 369 374
2. L.E. Adler, A. Olincy, M. Waldo, J.G. Harris, J. Griffith, K. Stevens, K. Flach, H. Nagamoto, P. Bickford, S. Leonard, and R. Freedman Schizophrenia, sensory gating, and nicotinic receptors Schizophr. Bull. 24 1998 189 202
3. Y. Ago, M. Sakaue, A. Baba, and T. Matsuda Selective reduction by isolation rearing of 5-HT1A receptor-mediated dopamine release in vivo in the frontal cortex of mice J. Neurochem. 83 2002 353 359
4. E.X. Albuquerque, E.F. Pereira, M. Alkondon, and S.W. Rogers Mammalian nicotinic acetylcholine receptors: from structure to function Physiol. Rev. 89 2009 73 120
5. Arime, Y.; Kasahara, Y.; Hall, F.S.; Uhl, G.R.; Sora, I. Cortico-subcortical neuromodulation involved in the amelioration of prepulse inhibition deficits in dopamine transporter knockout mice. Neuropsychopharmacology, in press.
6. Y. Arime, Y. Kubo, and I. Sora Animal models of attention-deficit/ hyperactivity disorder Biol. Pharm. Bull. 34 2011 1373 1376
7. A. Bancroft, and E.D. Levin Ventral hippocampal alpha4beta2 nicotinic receptors and chronic nicotine effects on memory Neuropharmacology 39 2000 2770 2778
8. E.A. Budygin, M.S. Brodie, T.D. Sotnikova, Y. Mateo, C.E. John, M. Cyr, R.R. Gainetdinov, and S.R. Jones Dissociation of rewarding and dopamine transporter-mediated properties of amphetamine Proc. Natl. Acad. Sci. U. S. A. 101 2004 7781 7786
9. P.W. Burnet, S.L. Eastwood, and P.J. Harrison [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia Neurochem. Int. 30 1997 565 574
10. F.P. Bymaster, J.S. Katner, D.L. Nelson, S.K. Hemrick-Luecke, P.G. Threlkeld, J.H. Heiligenstein, S.M. Morin, D.R. Gehlert, and K.W. Perry Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder Neuropsychopharmacology 27 2002 699 711
11. E. Carboni, C. Spielewoy, C. Vacca, M. Nosten-Bertrand, B. Giros, and G. Di Chiara Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene J. Neurosci. 21 RC141 2001 141 144
12. V. Castagne, P.C. Moser, and R.D. Porsolt Preclinical behavioral models for predicting antipsychotic activity Adv. Pharmacol. 57 2009 381 418
13. C.A. Conklin, N. Robin, K.A. Perkins, R.P. Salkeld, and F.J. McClernon Proximal versus distal cues to smoke: the effects of environments on smokers' cue-reactivity Exp. Clin. Psychopharmacol. 16 2008 207 214
14. G.W. Dalack, D.J. Healy, and J.H. Meador-Woodruff Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings Am. J. Psychiatry 155 1998 1490 1501
15. S.C. Dulawa, R. Hen, K. Scearce-Levie, and M.A. Geyer Serotonin1B receptor modulation of startle reactivity, habituation, and prepulse inhibition in wild-type and serotonin1B knockout mice Psychopharmacology (Berl.) 132 1997 125 134
16. S.M. Dursun, and S. Kutcher Smoking, nicotine and psychiatric disorders: evidence for therapeutic role, controversies and implications for future research Med. Hypotheses 52 1999 101 109
17. R.R. Gainetdinov, S.R. Jones, and M.G. Caron Functional hyperdopaminergia in dopamine transporter knock-out mice Biol. Psychiatry 46 1999 303 311
18. R.R. Gainetdinov, W.C. Wetsel, S.R. Jones, E.D. Levin, M. Jaber, and M.G. Caron Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity Science 283 1999 397 401
19. L. Galindo-Charles, S. Hernandez-Lopez, E. Galarraga, D. Tapia, J. Bargas, J. Garduno, C. Frias-Dominguez, R. Drucker-Colin, and S. Mihailescu Serotoninergic dorsal raphe neurons possess functional postsynaptic nicotinic acetylcholine receptors Synapse 62 2008 601 615
20. T.P. George, A. Termine, K.A. Sacco, T.M. Allen, E. Reutenauer, J.C. Vessicchio, and E.J. Duncan A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: involvement of nicotinic receptor mechanisms Schizophr. Res. 87 2006 307 315
21. M.A. Geyer, and S.C. Dulawa Assessment of murine startle reactivity, prepulse inhibition, and habituation Curr. Protoc. Neurosci. 2003 (Chapter 8), Unit 8 17
22. M.A. Geyer, and N.R. Swerdlow Measurement of startle response, prepulse inhibition, and habituation Curr. Protoc. Neurosci. 2001 (Chapter 8), Unit 8 7
23. S.G. Giakoumaki, P. Bitsios, and S. Frangou The level of prepulse inhibition in healthy individuals may index cortical modulation of early information processing Brain Res. 1078 2006 168 170
24. B. Giros, M. Jaber, S.R. Jones, R.M. Wightman, and M.G. Caron Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter Nature 379 1996 606 612
25. T.J. Gould, M. Rukstalis, and M.C. Lewis Atomoxetine and nicotine enhance prepulse inhibition of acoustic startle in C57BL/6 mice Neurosci. Lett. 377 2005 85 90
26. M.F. Green, P.D. Butler, Y. Chen, M.A. Geyer, S. Silverstein, J.K. Wynn, J.H. Yoon, and V. Zemon Perception measurement in clinical trials of schizophrenia: promising paradigms from CNTRICS Schizophr. Bull. 35 2009 163 181
27. F.S. Hall, X.F. Li, I. Sora, F. Xu, M. Caron, K.P. Lesch, D.L. Murphy, and G.R. Uhl Cocaine mechanisms: enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions Neuroscience 115 2002 153 161
28. F.S. Hall, A. Markou, E.D. Levin, and G.R. Uhl Mouse models for studying genetic influences on factors determining smoking cessation success in humans Ann. N. Y. Acad. Sci. 1248 2012 39 70
29. V. Kumari, and P. Postma Nicotine use in schizophrenia: the self medication hypotheses Neurosci. Biobehav. Rev. 29 2005 1021 1034
30. S. Leonard, C. Adams, C.R. Breese, L.E. Adler, P. Bickford, W. Byerley, H. Coon, J.M. Griffith, C. Miller, M. Myles-Worsley, H.T. Nagamoto, Y. Rollins, K.E. Stevens, M. Waldo, and R. Freedman Nicotinic receptor function in schizophrenia Schizophr. Bull. 22 1996 431 445
31. E.D. Levin, A. Bradley, N. Addy, and N. Sigurani Hippocampal alpha 7 and alpha 4 beta 2 nicotinic receptors and working memory Neuroscience 109 2002 757 765
32. E.D. Levin, P. Kim, and R. Meray Chronic nicotine working and reference memory effects in the 16-arm radial maze: interactions with D1 agonist and antagonist drugs Psychopharmacology (Berl.) 127 1996 25 30
33. B. Li, Y. Arime, F.S. Hall, G.R. Uhl, and I. Sora Impaired spatial working memory and decreased frontal cortex BDNF protein level in dopamine transporter knockout mice Eur. J. Pharmacol. 628 2010 104 107
34. S. Mihailescu, and R. Drucker-Colin Nicotine, brain nicotinic receptors, and neuropsychiatric disorders Arch. Med. Res. 31 2000 131 144
35. S. Mihailescu, R. Guzman-Marin, C. Dominguez Mdel, and R. Drucker-Colin Mechanisms of nicotine actions on dorsal raphe serotoninergic neurons Eur. J. Pharmacol. 452 2002 77 82
36. L.L. Miner Cocaine reward and locomotor activity in C57BL/6J and 129/SvJ inbred mice and their F1 cross Pharmacol. Biochem. Behav. 58 1997 25 30
37. H. Mizoguchi, S. Arai, H. Koike, D. Ibi, H. Kamei, T. Nabeshima, H.C. Kim, K. Takuma, and K. Yamada Therapeutic potential of nicotine for methamphetamine-induced impairment of sensorimotor gating: involvement of pallidotegmental neurons Psychopharmacology (Berl.) 207 2009 235 243
38. E. Morice, J.M. Billard, C. Denis, F. Mathieu, C. Betancur, J. Epelbaum, B. Giros, and M. Nosten-Bertrand Parallel loss of hippocampal LTD and cognitive flexibility in a genetic model of hyperdopaminergia Neuropsychopharmacology 32 2007 2108 2116
39. J.A. Moron, A. Brockington, R.A. Wise, B.A. Rocha, and B.T. Hope Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines J. Neurosci. 22 2002 389 395
40. Q. Mu, K. Johnson, P.S. Morgan, E.L. Grenesko, C.E. Molnar, B. Anderson, Z. Nahas, F.A. Kozel, S. Kose, M. Knable, P. Fernandes, D.E. Nichols, R.B. Mailman, and M.S. George A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia Schizophr. Res. 94 2007 332 341
41. C.P. Muller, M.A. De Souza Silva, G. DePalma, C. Tomaz, R.J. Carey, and J.P. Huston The selective serotonin(1A)-receptor antagonist WAY 100635 blocks behavioral stimulating effects of cocaine but not ventral striatal dopamine increase Behav. Brain Res. 134 2002 337 346
42. A. Olincy, J.G. Harris, L.L. Johnson, V. Pender, S. Kongs, D. Allensworth, J. Ellis, G.O. Zerbe, S. Leonard, K.E. Stevens, J.O. Stevens, L. Martin, L.E. Adler, F. Soti, W.R. Kem, and R. Freedman Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia Arch. Gen. Psychiatry 63 2006 630 638
43. N. Petrovsky, B.B. Quednow, U. Ettinger, A. Schmechtig, R. Mossner, D.A. Collier, K.U. Kuhn, W. Maier, M. Wagner, and V. Kumari Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers Neuropsychopharmacology 35 2010 1429 1439
44. M.R. Picciotto, B.J. Caldarone, S.L. King, and V. Zachariou Nicotinic receptors in the brain. Links between molecular biology and behavior Neuropsychopharmacology 22 2000 451 465
45. A.S. Potter, P.A. Newhouse, and D.J. Bucci Central nicotinic cholinergic systems: a role in the cognitive dysfunction in attention-deficit/hyperactivity disorder? Behav. Brain Res. 175 2006 201 211
46. S.B. Powell, J.W. Young, J.C. Ong, M.G. Caron, and M.A. Geyer Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice Behav. Pharmacol. 19 2008 562 565
47. S.B. Powell, X. Zhou, and M.A. Geyer Prepulse inhibition and genetic mouse models of schizophrenia Behav. Brain Res. 204 2009 282 294
48. R.J. Ralph, M.P. Paulus, F. Fumagalli, M.G. Caron, and M.A. Geyer Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists J. Neurosci. 21 2001 305 313
49. N. Ripoll, M. Bronnec, and M. Bourin Nicotinic receptors and schizophrenia Curr. Med. Res. Opin. 20 2004 1057 1074
50. H. Rollema, Y. Lu, A.W. Schmidt, J.S. Sprouse, and S.H. Zorn 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex Biol. Psychiatry 48 2000 229 237
51. H. Rollema, Y. Lu, A.W. Schmidt, and S.H. Zorn Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation Eur. J. Pharmacol. 338 1997 R3 R5
52. R. Sack, A. Gochberg-Sarver, U. Rozovsky, M. Kedmi, S. Rosner, and A. Orr-Urtreger Lower core body temperature and attenuated nicotine-induced hypothermic response in mice lacking the beta4 neuronal nicotinic acetylcholine receptor subunit Brain Res. Bull. 66 2005 30 36
53. M. Sakaue, Y. Ago, A. Baba, and T. Matsuda The 5-HT1A receptor agonist MKC-242 reverses isolation rearing-induced deficits of prepulse inhibition in mice Psychopharmacology (Berl.) 170 2003 73 79
54. M. Sakaue, P. Somboonthum, B. Nishihara, Y. Koyama, H. Hashimoto, A. Baba, and T. Matsuda Postsynaptic 5-hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex Br. J. Pharmacol. 129 2000 1028 1034
55. M. Sarter, V. Parikh, and W.M. Howe nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms Biochem. Pharmacol. 78 2009 658 667
56. R. Schreiber, M. Dalmus, and J. De Vry Effects of alpha 4/beta 2- and alpha 7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice Psychopharmacology (Berl.) 159 2002 248 257
57. N.A. Shanahan, K.A. Holick Pierz, V.L. Masten, C. Waeber, M. Ansorge, J.A. Gingrich, M.A. Geyer, R. Hen, and S.C. Dulawa Chronic reductions in serotonin transporter function prevent 5-HT1B-induced behavioral effects in mice Biol. Psychiatry 65 2009 401 408
58. E. Shearman, S. Fallon, H. Sershen, and A. Lajtha Nicotine-induced monoamine neurotransmitter changes in the brain of young rats Brain Res. Bull. 76 2008 626 639
59. H.W. Shen, Y. Hagino, H. Kobayashi, K. Shinohara-Tanaka, K. Ikeda, H. Yamamoto, T. Yamamoto, K.P. Lesch, D.L. Murphy, F.S. Hall, G.R. Uhl, and I. Sora Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters Neuropsychopharmacology 29 2004 1790 1799
60. I. Sora, F.S. Hall, A.M. Andrews, M. Itokawa, X.F. Li, H.B. Wei, C. Wichems, K.P. Lesch, D.L. Murphy, and G.R. Uhl Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference Proc. Natl. Acad. Sci. U. S. A. 98 2001 5300 5305
61. I. Sora, C. Wichems, N. Takahashi, X.F. Li, Z. Zeng, R. Revay, K.P. Lesch, D.L. Murphy, and G.R. Uhl Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice Proc. Natl. Acad. Sci. U. S. A. 95 1998 7699 7704
62. Soria-Fregozo, C.F.-S.; Pérez-Vega, M.E.; Feria-Velasco, M.I.; Feria-Velasco, A. 5-HT denervation of the adult rat prefrontal cortex induces changes in the expression of α4 and α7 nicotinic acetylcholine receptor subtypes. Neurologia, in press.
63. C. Spielewoy, G. Biala, C. Roubert, M. Hamon, C. Betancur, and B. Giros Hypolocomotor effects of acute and daily d-amphetamine in mice lacking the dopamine transporter Psychopharmacology (Berl.) 159 2001 2 9
64. T. Sumiyoshi, S. Park, K. Jayathilake, A. Roy, A. Ertugrul, and H.Y. Meltzer Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study Schizophr. Res. 95 2007 158 168
65. N.R. Swerdlow, G.A. Light, K.S. Cadenhead, J. Sprock, M.H. Hsieh, and D.L. Braff Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function Arch. Gen. Psychiatry 63 2006 1325 1335
66. K. Wedzony, A. Chocyk, W. Kolasiewicz, and M. Mackowiak Glutamatergic neurons of rat medial prefrontal cortex innervating the ventral tegmental area are positive for serotonin 5-HT1A receptor protein J. Physiol. Pharmacol. 58 2007 611 624
67. S. Weiss, E.T. Tzavara, R.J. Davis, G.G. Nomikos, J. Michael McIntosh, B. Giros, and M.P. Martres Functional alterations of nicotinic neurotransmission in dopamine transporter knock-out mice Neuropharmacology 52 2007 1496 1508
68. T.E. Wilens, and M.W. Decker Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition Biochem. Pharmacol. 74 2007 1212 1223
69. M. Yamashita, S. Fukushima, H.W. Shen, F.S. Hall, G.R. Uhl, Y. Numachi, H. Kobayashi, and I. Sora Norepinephrine transporter blockade can normalize the prepulse inhibition deficits found in dopamine transporter knockout mice Neuropsychopharmacology 31 2006 2132 2139
70. F.M. Zhou, Y. Liang, and J.A. Dani Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum Nat. Neurosci. 4 2001 1224 1229